NLRP3 blockade by MCC950 suppressed osteoclastogenesis via NF-κB/c-Fos/NFATc1 signal pathway and alleviated bone loss in diabetes mellitus
Molecular and Cellular Endocrinology · 2024-12 · 594 · 112382
DOI: 10.1016/j.mce.2024.112382 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular and Cellular Endocrinology, 2024-12. Verfasst von Guoping Cai und 8 weiteren Autor:innen. Beteiligte Einrichtung: Orthopedic Department, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Taizhou, China. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Furans, Sulfonamides, Signal Transduction. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Science and Technology Plan Project of Taizhou, Zhejiang Province Basic Public Welfare Research Program, National Natural Science Foundation of China.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Obesity and type 2 diabetes mellitus (T2DM) are linked to osteoporosis development, with obesity being a significant risk factor for T2DM. T2DM patients with obesity exhibit a higher fracture rate and often have a poor prognosis post-fracture. To address the urgent need for understanding the mechanisms of diabetic osteoporosis (DOP), research is ongoing to explore how obesity and T2DM impact bone metabolism. The NLRP3 inflammasome has been implicated in the pathogenesis of osteoporosis, and MCC950, an NLRP3 inflammasome inhibitor, has shown promise in various diseases but its role in osteoporosis remains unexplored. In this study, BMMs and BMSCs were isolated and cultured to investigate the effects of MCC950 on bone metabolism, and DOP model was used to evaluate the efficacy of MCC950 in vivo. The study demonstrated that MCC950 treatment inhibited osteoclast differentiation, reduced bone resorption capacity in BMMs without suppression for osteoblast differentiation from BMSCs. Additionally, MCC950 suppressed the activation of the NF-κB signaling pathway and downregulated key factors associated with osteoclast differentiation. Additionally, MCC950 alleviated bone loss in DOP mouse. These findings suggest that MCC950, by targeting the NLRP3 inflammasome, may have a protective role in preventing osteoporosis induced by T2DM with obesity. The study highlights the potential therapeutic implications of MCC950 in managing diabetic osteoporosis and calls for further research to explore its clinical application in high-risk patient populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Orthopedic Department, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Taizhou, China.
- Orthopedic Department, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Taizhou, China. Electronic address: medchx@126.com.
- Orthopedic Department, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Taizhou, China; Institute of Bone Metabolism, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Taizhou, China.…
Förderung
- Science and Technology Plan Project of Taizhou
- Zhejiang Province Basic Public Welfare Research Program
- National Natural Science Foundation of China
Zitieren
APA
Cai, G., Song, X., Luo, H., Dai, G., Zhang, H., Jiang, D., Lei, X., Chen, H., & Zhang, L. (2024). NLRP3 blockade by MCC950 suppressed osteoclastogenesis via NF-κB/c-Fos/NFATc1 signal pathway and alleviated bone loss in diabetes mellitus. Molecular and Cellular Endocrinology, 594, 112382. https://doi.org/10.1016/j.mce.2024.112382
Vancouver
Cai G, Song X, Luo H, Dai G, Zhang H, Jiang D, et al. NLRP3 blockade by MCC950 suppressed osteoclastogenesis via NF-κB/c-Fos/NFATc1 signal pathway and alleviated bone loss in diabetes mellitus. Molecular and Cellular Endocrinology. 2024;594:112382. doi:10.1016/j.mce.2024.112382
BibTeX
@article{Cai2024,
author = {Cai, Guoping and Song, Xiaoting and Luo, Hua and Dai, Gaoyuan and Zhang, Honghao and Jiang, Dengteng and Lei, Xinhuan and Chen, Haixiao and Zhang, Liwei},
title = {NLRP3 blockade by MCC950 suppressed osteoclastogenesis via NF-κB/c-Fos/NFATc1 signal pathway and alleviated bone loss in diabetes mellitus},
journal = {Molecular and Cellular Endocrinology},
year = {2024},
volume = {594},
pages = {112382},
doi = {10.1016/j.mce.2024.112382}
}
EUVIMED